AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Brainsway Ltd (NASDAQ:BWAY)
14.63 USD
-0.060 0.408%Sponsored Reports
Loading...
| Previous Close (in USD) | 14.69 |
|---|---|
| Change | -0.060 0.408% |
| 52 W H/L (in USD) | 16.265/4.295 |
| EBITDA (in USD) | 5.861M |
| PE Ratio | 85.17 |
| Volume | 44175 |
| Diluted Eps TTM | 0.18 |
| Total Assets (in USD) | 112.915M |
|---|---|
| Total Liabilities (in USD) | 34.666M |
| Revenue TTM (in USD) | 52.225M |
| Cash (in USD) | 67.95M |
| Market Cap (in USD) | 614.950 M |
| Revenue Per Share TTM | 1.368 |
| Gross Profit TTM (in USD) | 39.386M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Employees: 120
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Christopher R. von Jako Ph.D. | Pres & CEO | 1969 |
| 2. | Mr. Richard Scott Areglado | Sr. VP & CFO | 1964 |
| 3. | Mr. Hadar Levy | Sr. VP & COO | 1974 |
| 4. | Mr. Christopher J. Boyer Ph.D. | VP of Global Marketing | 1978 |
| 5. | Mr. Avner Hagai | Founder & Independent Vice-Chairman | 1956 |
| 6. | Prof. Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director | 1970 |
| 7. | Dr. Yiftach Roth Ph.D. | Chief Scientist | 1971 |
| 8. | Mr. Menachem C. Klein Esq. | VP, Gen. Counsel & Corp. Sec. | NA |
| 9. | Dr. Aron Tendler | Chief Medical Officer | NA |
| 10. | Ms. Moria Ankri | VP R&D | 1984 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
-1.470 1.640% | 89.62 | 25.970 | 17.241 | 3.570 | 3.200 | 3.805 | 16.753 |
|
SYK
Stryker Corporation |
+6.560 2.146% | 308.28 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
-0.130 0.162% | 80.58 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
-0.260 0.551% | 47.6 | 31.490 | 17.241 | 4.407 | 3.650 | 4.878 | 19.194 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | 7.771M | 3.459M | -3.946M | -13.034M | -6.419M |
| Minority Interest | - | - | - | - | - |
| Net Income | 7.694M | 2.921M | -4.197M | -13.349M | -6.462M |
| Selling General Administrative | 25.46M | 5.797M | 15.718M | 6.854M | 5.784M |
| Gross Profit | 39.698M | 30.581M | 23.477M | 20.048M | 23.058M |
| Reconciled Depreciation | 1.538M | 1.771M | 1.34M | 1.535M | 1.686M |
| Ebit | 4.357M | 3.586M | -3.898M | -12.683M | -4.999M |
| Ebitda | 5.907M | 5.357M | -2.561M | -11.148M | -3.313M |
| Depreciation And Amortization | 1.55M | 1.771M | 1.337M | 1.535M | 1.686M |
| Operating Income | 4.357M | 1.391M | -4.959M | -12.683M | -4.999M |
| Other Operating Expenses | 48.282M | 39.625M | 36.744M | 39.86M | 34.656M |
| Interest Expense | 2.227M | 1.356M | 0.298M | 0.046M | 1.42M |
| Tax Provision | 0.077M | 0.538M | 0.36M | 0.315M | 0.043M |
| Interest Income | 5.596M | 2.477M | 2.171M | 1.109M | 0.225M |
| Net Interest Income | 3.387M | 1.121M | 1.879M | -0.351M | -1.42M |
| Income Tax Expense | 0.078M | 0.538M | 0.251M | 0.315M | 0.043M |
| Total Revenue | 52.639M | 41.016M | 31.785M | 27.177M | 29.657M |
| Total Operating Expenses | 35.341M | 29.19M | 28.436M | 32.731M | 28.057M |
| Cost Of Revenue | 12.941M | 10.435M | 8.308M | 7.129M | 6.599M |
| Total Other Income Expense Net | 3.414M | 2.068M | 1.013M | -0.351M | -1.42M |
| Net Income From Continuing Ops | 7.633M | 2.921M | -8.191M | -13.349M | -6.462M |
| Net Income Applicable To Common Shares | - | - | - | -13.349M | -6.462M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 112.915M | 94.316M | 62.972M | 64.477M | 75.732M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 5.693M | 1.303M | 1.712M | 1.556M | 1.766M |
| Total Liab | 34.666M | 32.003M | 15.314M | 19.08M | 18.408M |
| Total Stockholder Equity | 73.22M | 62.313M | 41.581M | 45.397M | 57.324M |
| Other Current Liab | 8.109M | 5.659M | 6.267M | 5.314M | 5.27M |
| Common Stock | 0.43M | 0.413M | 0.367M | 0.364M | 0.362M |
| Capital Stock | 0.43M | 0.413M | 0.367M | 0.364M | 0.363M |
| Retained Earnings | -90.747M | -98.381M | -101.302M | -97.105M | -83.756M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.143M | 0M | 1.042M | 0.954M |
| Cash | 67.95M | 69.345M | 10.791M | 47.581M | 16.921M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 22.163M | 15.346M | 9.761M | 8.141M | 9.068M |
| Current Deferred Revenue | 10.551M | 5.727M | 2.504M | 1.477M | 2.195M |
| Net Debt | -61.133M | -63.721M | -10.32M | -47.093M | -16.167M |
| Short Term Debt | 1.075M | 0.824M | 0.232M | 0.234M | 0.5M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 6.817M | 5.624M | 0.471M | 0.488M | 0.754M |
| Other Stockholder Equity | 162.218M | 162.469M | 140.344M | 144.326M | 142.906M |
| Property Plant Equipment | - | - | - | 5.346M | 9.331M |
| Total Current Assets | 84.888M | 79.67M | 55.465M | 58.089M | 65.447M |
| Long Term Investments | 14.337M | - | - | - | - |
| Short Term Investments | 1.432M | 0M | 35.465M | 0.271M | 40.428M |
| Net Receivables | 4.111M | 4.596M | 3.78M | 4.844M | 6.332M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 7.134M | 4.426M | 3.717M | 3.837M | 0.2M |
| Accounts Payable | 2.428M | 2.868M | 0.758M | 1.116M | 1.103M |
| Accumulated Other Comprehensive Income | 1.318M | -2.188M | 2.172M | -2.188M | -2.188M |
| Non Currrent Assets Other | 1.523M | 1.635M | 0.889M | 1.042M | 0.954M |
| Non Current Assets Total | 28.028M | 14.646M | 7.507M | 6.388M | 10.285M |
| Capital Lease Obligations | 6.817M | 5.624M | 0.471M | 0.488M | 0.754M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -15.766M | 30.311M | -1.526M | 42.169M | -40M |
| Total Cashflows From Investing Activities | -17.632M | 30.311M | -37.409M | 42.169M | -42.216M |
| Total Cash From Financing Activities | -2.232M | 18.263M | -1.026M | -1.546M | 41.516M |
| Net Income | 7.694M | 2.921M | -4.197M | -13.349M | -6.462M |
| Change In Cash | -1.666M | 58.825M | -37.061M | 30.66M | -0.04M |
| Begin Period Cash Flow | 69.616M | 10.52M | 47.581M | 16.921M | 16.961M |
| End Period Cash Flow | 67.95M | 69.345M | 10.52M | 47.581M | 16.921M |
| Total Cash From Operating Activities | 18.163M | 10.298M | 1.284M | -9.759M | 0.884M |
| Depreciation | 1.55M | 1.771M | 1.337M | 1.535M | 1.686M |
| Other Cashflows From Investing Activities | - | 35.076M | -35.022M | -0.021M | 0.022M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -2.005M | -0.92M | -0.506M | -3.595M | -0.411M |
| Sale Purchase Of Stock | - | 0M | 0M | -0.052M | - |
| Other Cashflows From Financing Activities | -2.232M | 2.334M | -0.755M | -0.962M | -0.269M |
| Capital Expenditures | 1.761M | 3.794M | 2.387M | 1.936M | 2.238M |
| Change In Working Capital | 7.646M | 2.387M | 1.635M | -1.454M | 1.068M |
| Other Non Cash Items | 1.273M | 1.799M | 1.877M | 1.72M | 2.656M |
| Free Cash Flow | 16.402M | 6.504M | -1.103M | -7.823M | -1.354M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | 1290 Essex Small Cap Growth I | 3 months ago | 67735 |
| 2. | Pleiades Small Cap Equity A | 5 months ago | 46614 |
| 3. | Steward Values Enhanced International I | 2 months ago | 29962 |
| 4. | ActivePassive International Equity ETF | 2 months ago | 28095 |
| 5. | Even Herd Long Short ETF | 2 months ago | 15055 |
| 6. | ARK Israel Innovative Technology ETF | 2 months ago | 193686 |
| 7. | Royce Smaller-Companies Growth Svc | 2 months ago | 97000 |
| 8. | Timothy Plan Israel Common Values A | 5 months ago | 81303 |
| 9. | Mandarine Global Microcap G EUR | 5 months ago | 10800 |
| 10. | Essex Inv Mgt Micro Cap Growth | 5 months ago | 6830 |
| 11. | Fidelity Nasdaq Composite Index | 3 months ago | 5012 |
| 12. | Voya Multi-Manager International Sm Cp A | 4 months ago | 4917 |
| 13. | Sun Life Global Mid Cap Fund I | 3 months ago | 4056 |
| 14. | iShares Neuroscience and Healthcare ETF | 2 months ago | 1869 |
| 15. | Essex Small Growth | 5 months ago | 1198 |
| 16. | Blackstone Alternative Multi-Strategy I | 8 months ago | 700 |
| 17. | IMC Non-US Micro Cap | 2 months ago | 230 |
| 18. | IMC Global Micro Cap | 2 months ago | 65 |
| 19. | Man Balanced Managed Retail Acc A | 9 months ago | 29 |
| 20. | UWS GLG Stockmarket Managed B | 9 months ago | 15 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Valor Management LLC | 5 months ago | 2657475 |
| 2. | Masters Capital Management LLC | 5 months ago | 1000000 |
| 3. | Essex Investment Management Company, LLC | 5 months ago | 304180 |
| 4. | Renaissance Technologies Corp | 5 months ago | 276860 |
| 5. | Cresset Asset Management, LLC | 5 months ago | 157462 |
| 6. | ARK Investment Management LLC | 5 months ago | 127331 |
| 7. | Y.D. More Investments Ltd | 5 months ago | 114962 |
| 8. | Legato Capital Management LLC | 5 months ago | 97376 |
| 9. | Huntleigh Advisors Inc | 5 months ago | 87076 |
| 10. | Eagle Global Advisors, LLC | 5 months ago | 81303 |
| 11. | Two Sigma Advisers, LLC | 5 months ago | 76800 |
| 12. | Two Sigma Investments LLC | 5 months ago | 75691 |
| 13. | UBS Group AG | 8 months ago | 63878 |
| 14. | Morgan Stanley - Brokerage Accounts | 8 months ago | 43492 |
| 15. | JPMorgan Chase & Co | 8 months ago | 43278 |
| 16. | Citadel Advisors Llc | 5 months ago | 25926 |
| 17. | The Goldman Sachs Group Inc | 5 months ago | 25738 |
| 18. | Rhumbline Advisers | 5 months ago | 22265 |
| 19. | Wells Fargo & Co | 8 months ago | 20118 |
| 20. | Susquehanna International Group, LLP | 5 months ago | 19473 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...